Belgian INAMI/RIZIV updated the List of reimbursable implants and medical devices

16

Jan 2020

New material codes for implantable non-rechargeable neurostimulator, electrodes, and extensions for stimulation of the dorsal root nodes were added to the List of reimbursable devices of the Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) in December 2019.

New material codes and related conditions of reimbursement have been implemented for the following devices:

Implantable non-rechargeable neurostimulator, electrodes, and extensions for stimulation of the dorsal root nodes

  • Devices will be reimbursed by individual price (tariff determined individually for each brand name) when registered in the Nominative lists 37701, 37801 and 37901
  • The following material codes have been applied:
    • 174532 - 174543 “Fully implanted non-rechargeable neurostimulator for stimulation of the dorsal root nodes, including the patient programmer” with the tariff of €9,170;
    • 174554 - 174565 “Fully implanted, non-rechargeable replacement neurostimulator for stimulating the dorsal root glands, including the patient programmer” with the tariff of €9,170;
    • 174576 - 174580 “Fully implanted non-rechargeable replacement neurostimulator, for stimulation of the dorsal root glands, including the patient programmer, in the event of early replacement” with the tariff of €9,170;
    • 174591 - 174602 “All of the implanted electrodes and extensions, for the stimulation of the dorsal root ganglia, for surgical or percutaneous placement, per intervention” with the tariff of €1,090;
    • 174613 - 174624 “Set of implanted replacement electrodes and extensions for stimulation of the dorsal root ganglia, for surgical or percutaneous placement, per intervention” with the tariff of €1,090;
    • 174635 - 174646 “Set of implanted replacement extensions for stimulation of the dorsal root ganglia, for surgical or percutaneous placement, per intervention” with the tariff of €169;
    • 174650 - 174661 “All electrodes and extensions in the event of negative test stimulation for stimulation of the dorsal root ganglia, for surgical or percutaneous placement, per intervention” with the tariff of €1,090;
  • There are specific conditions of reimbursement for these technologies, provided in paragraph B-§13 of the List of reimbursable implants and medical devices.

See the updated version of the List of the reimbursable devices in French and Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.

The latest related news

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more

08

Mar 2022

At the end of February 2022, the Dental and Pharmaceutical Benefits Agency (TLV) has launched a theme survey on products for monitoring and diagnostics of sepsis to identify products that may be relevant for health economic assessments at TLV. The suggestions for the products of interest, ongoing clinical studies, or innovation projects could be received until 23 March 2022.

Read more

07

Mar 2022

On February 08, 2022, the Reimbursement Commission of the Social Security Institution released an updated version of the Healthcare Implementation Communique. The main changes relate to the increase in reimbursement fees of services and medical devices by approximately 35-75%.

Read more